Yesterday, May 3, 2016, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $503.53 to $7,621,855.35. Highlighted Stocks Traded by Insiders: Salesforce.com (CRM) - FREE Research Report Roos John Victor, who is Director at Salesforce.com, sold 180 shares at $76.40 on May 3, 2016. Following this transaction, the Director owned 17,314 shares meaning that the stake was reduced by 1.03% with the 180-share transaction. The shares most recently traded at $74.14, down $2.26, or 3.05% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 213,440
  • 12-Week # shares sold: 698,337
  • 24-Week # shares sold: 1.5 million
The average volume for Salesforce.com has been 4.9 million shares per day over the past 30 days. Salesforce.com has a market cap of $51.8 billion and is part of the technology sector and computer software & services industry. Shares are down 4.46% year-to-date as of the close of trading on Tuesday. salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 24 analysts who rate Salesforce.com a buy, no analysts rate it a sell, and 3 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on CRM - FREE TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report Mahoney Michael F, who is President & CEO at Boston Scientific, sold 100,000 shares at $22.12 on May 3, 2016. Following this transaction, the President & CEO owned 1.6 million shares meaning that the stake was reduced by 5.77% with the 100,000-share transaction. The shares most recently traded at $21.78, down $0.34, or 1.57% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 39,927
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 439,178
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 522,901
The average volume for Boston Scientific has been 9.7 million shares per day over the past 30 days. Boston Scientific has a market cap of $29.7 billion and is part of the health care sector and health services industry. Shares are up 18.11% year-to-date as of the close of trading on Tuesday. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 15 analysts who rate Boston Scientific a buy, no analysts rate it a sell, and 5 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on BSX - FREE TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Dixie Group (DXYN) - FREE Research Report Blue William F JR, who is Director at Dixie Group, bought 877 shares at $4.72 on May 3, 2016. Following this transaction, the Director owned 4,809 shares meaning that the stake was boosted by 22.3% with the 877-share transaction. The shares most recently traded at $4.34, down $0.38, or 8.76% since the insider transaction. Historical insider transactions for Dixie Group go as follows:

  • 4-Week # shares bought: 970
  • 4-Week # shares sold: 11,242
  • 12-Week # shares bought: 970
  • 12-Week # shares sold: 11,242
  • 24-Week # shares bought: 6,970
  • 24-Week # shares sold: 11,242
The average volume for Dixie Group has been 26,600 shares per day over the past 30 days. Dixie Group has a market cap of $75.6 million and is part of the industrial goods sector and industrial industry. Shares are down 11.63% year-to-date as of the close of trading on Tuesday. The Dixie Group, Inc. manufactures, markets, and sells carpets and rugs for residential and commercial applications primarily in the United States. Currently, there is 1 analyst who rates Dixie Group a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on DXYN - FREE TheStreet Quant Ratings rates Dixie Group as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and poor profit margins. Get the full Dixie Group Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.